Rafferty Asset Management LLC Purchases 25,902 Shares of Celldex Therapeutics, Inc. $CLDX

Rafferty Asset Management LLC increased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 36.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,460 shares of the biopharmaceutical company’s stock after acquiring an additional 25,902 shares during the quarter. Rafferty Asset Management LLC owned about 0.15% of Celldex Therapeutics worth $2,521,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at about $26,000. Nisa Investment Advisors LLC boosted its stake in Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics in the 3rd quarter valued at approximately $42,000. Russell Investments Group Ltd. increased its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the third quarter worth approximately $63,000.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $29.54 on Thursday. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $31.31. The firm has a market capitalization of $1.97 billion, a PE ratio of -7.59 and a beta of 1.17. The company’s fifty day moving average price is $25.86 and its two-hundred day moving average price is $25.61.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. Analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CLDX shares. Stifel Nicolaus restated a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. The Goldman Sachs Group increased their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday. Barclays boosted their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.